BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial - Eriksson, BI; Dahl, OE; Büller, HR (J Thromb Haemost, 2005)
et al.